PAP
STOK icon

Persistent Asset Partners’s Stoke Therapeutics STOK Stock Holding History

Persistent Asset Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,576
Closed -$145K – 464
2025
Q4 		$145K Buy
+4,576
New +$138K 0.07% 245

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Persistent Asset Partners's STOK Position: Q1 2026 in Review

Persistent Asset Partners sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 4,576 shares — an estimated $145K sold.

Persistent Asset Partners first reported a position in STOK in Q4 2025 and held it in 1 quarter. The position peaked at $145K in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Persistent Asset Partners reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 4,576 Stoke Therapeutics shares in Q1 2026, an estimated $145K.
  • Persistent Asset Partners first reported a position in Stoke Therapeutics in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Stoke Therapeutics position peaked at $145K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.